Arkray Healthcare Private Limited

Arkray Healthcare Private Limited, incorporated on October 17, 2007, is a private company registered in Mumbai, Maharashtra, India. The company operates under the Corporate Identification Number (CIN) U51507MH2007PTC175112 and is classified as a non-government company. Its authorized share capital is ₹1,660,000,000, with a paid-up capital of ₹1,659,000,000. The registered office is located at 7th Floor, Opulence, 6th Road, TPS III, Santacruz East, Mumbai, Maharashtra 400055, India.

Arkray Healthcare Private Limited is a wholly owned subsidiary of ARKRAY Inc., Japan, which acquired the in vitro diagnostics (IVD) business of Span Diagnostics Limited. The company specializes in the research, development, manufacturing, distribution, and after-sales services of clinical testing instruments, reagents, and data management systems used for diagnosis, treatment, and medical examinations. Its product portfolio includes urine test strips, blood glucose systems, analyzers for diabetes testing, hematology testing, urinalysis, and lactate testing systems for athletes.

Arkray Healthcare Private Limited operates manufacturing facilities in Surat, Gujarat, India. The Surat plant specializes in the production of medical devices and diagnostic products, including urine test strips, blood glucose systems, and analyzers for diabetes testing. This facility supports the company's commitment to delivering high-quality diagnostic solutions to the Indian market and beyond.

The leadership team at Arkray Healthcare Private Limited comprises:

• Yukitoshi Yao: Director since September 29, 2008.

• Tadashi Inoue: Director since April 1, 2010.

• Hiroshi Junichiro Hyodo: Director since January 31, 2017.

• Kenji Yoshihara: Director.

• Pankaj Kantilal Ajmera: Director.

Arkray Healthcare Private Limited's products are subject to regulatory approvals in various international markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has established a strong presence in these regions by obtaining necessary certifications and approvals for its diagnostic products. This includes compliance with the U.S. Food and Drug Administration (FDA) regulations, European Medicines Agency (EMA) standards, and other relevant regulatory bodies. The company's adherence to these standards ensures the safety and efficacy of its products in these markets.

Arkray Healthcare Private Limited has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are prequalified by the World Health Organization (WHO), facilitating access to these regions. This prequalification enables the company to supply its diagnostic products to countries with stringent regulatory requirements, thereby enhancing its global footprint.

The company's geographic strategy involves diversification across multiple international markets, including the U.S., EU, UK, Australia, Japan, Africa, Latin America, and Southeast Asia. This approach mitigates concentration risk and positions Arkray Healthcare Private Limited to leverage growth opportunities in various regions. The strategic direction focuses on expanding market presence and enhancing customer satisfaction through high-quality diagnostic solutions.

Arkray Healthcare Private Limited's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA). The company has obtained approvals for its Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs), ensuring compliance with FDA standards. The facilities have undergone FDA inspections, which have been completed satisfactorily, confirming adherence to Good Manufacturing Practices (GMP). This compliance underscores the company's commitment to producing safe and effective diagnostic products for the U.S. market.

Arkray Healthcare Private Limited's manufacturing facilities hold certifications from the World Health Organization (WHO) and comply with European Union Good Manufacturing Practices (EU GMP). These certifications affirm the company's commitment to maintaining high-quality manufacturing standards for its diagnostic products. The facilities are also listed in the European Directorate for the Quality of Medicines & HealthCare (EDQM) database, further validating their compliance with international quality standards.

In India, Arkray Healthcare Private Limited holds manufacturing licenses issued by the Central Drugs Standard Control Organisation (CDSCO). The company has obtained approvals from state drug controllers and possesses the necessary export No Objection Certificates (NOCs), enabling it to distribute its diagnostic products both domestically and internationally. These regulatory approvals ensure that the company's products meet the safety and efficacy standards required by Indian authorities.

As of March 28, 2026, there have been no reported Form 483 observations, warning letters, or import alerts issued by regulatory bodies against Arkray Healthcare Private Limited. This indicates that the company's manufacturing facilities and products are in good standing with regulatory authorities, reflecting its commitment to compliance and quality.

Arkray Healthcare Private Limited operates in a competitive landscape with several key players in the medical devices and diagnostics sector. Top competitors include companies such as Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers. In the Indian market, Arkray Healthcare holds a significant position, with its top three products—Reagent, Diagnostic, and Kit—accounting for 24.8%, 17.6%, and 0.7% market share, respectively. This market share distribution indicates a strong presence in the diagnostic sector, with opportunities for growth in other product categories.

Arkray Healthcare Private Limited's key differentiators include its comprehensive product portfolio, which spans various diagnostic categories, and its commitment to quality, as evidenced by certifications from WHO and EU GMP. The company's focus on customer support and sales and marketing has enabled it to serve over 100,000 customers and more than 2,000 healthcare professionals and hospitals across India. These strengths position the company as a reliable and customer-centric provider of diagnostic solutions.

Arkray Healthcare Private Limited's current strategic direction focuses on expanding its presence in the generics and specialty diagnostics markets. The company's adherence to international quality standards and its robust manufacturing capabilities support this strategy. Looking ahead, the company aims to enhance its product offerings and market reach, leveraging its existing strengths to achieve sustainable growth and maintain a competitive edge in the global diagnostics industry.

Arkray Healthcare Private Limited has a strong track record in the diagnostics sector, with a total export value of $9.6 million USD and 1,920 shipments across three products in one therapeutic category. The company's portfolio concentration, with its top three products accounting for 42.9% of the market share, indicates a focused approach to product development and market penetration. The company's adherence to international quality standards and its commitment to customer satisfaction further enhance its reliability as a supplier.

Importers should verify the following certifications when considering Arkray Healthcare Private Limited as a supplier:

• FDA Registration: Confirm the company's manufacturing facilities are registered with the U.S. Food and Drug Administration.

• WHO-GMP Certification: Ensure the company holds certification from the World Health Organization's Good Manufacturing Practices.

• EU GMP Certification: Verify compliance with European Union Good Manufacturing Practices.

• ISO Certification: Check for relevant International Organization for Standardization certifications related to quality management systems.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting the company directly.

When conducting due diligence on Arkray Healthcare Private Limited, consider the following steps:

• Verify Regulatory Approvals: Confirm the company's compliance with FDA, WHO-GMP, EU GMP, and ISO standards.

• Assess Financial Health: Review the company's financial statements for the latest fiscal year to evaluate profitability and financial stability.

• Evaluate Product Portfolio: Examine the range and quality of products offered, focusing on their market performance and customer feedback.

• Inspect Manufacturing Facilities: If possible, conduct site visits to assess manufacturing capabilities and adherence to quality standards.